Elizabeth C. Hsia

5.3k citations

109 papers · 3.9k indexed · 3 hit papers · h-index 34

Co-authors: Mahboob U. Rahman Jonathan Kay Eric L. Matteson Mittie K. Doyle Sudha Visvanathan Yiying Zhou Roy Fleischmann Atul Deodhar
Topics: Rheumatoid Arthritis Research and Therapies (67 papers)Autoimmune and Inflammatory Disorders Research (53 papers)Spondyloarthritis Studies and Treatments (40 papers)
Cited by: Rheumatology Hematology Immunology
Journals: The Lancet Annals of the Rheumatic Diseases Journal of Investigative Dermatology
Partner nations: United States United Kingdom Canada

In The Last Decade

Elizabeth C. Hsia

106 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 423 citations Josef S Smolen, Jonathan Kay et al. The Lancet profile →
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

2020 242 citations Philip J. Mease, Proton Rahman et al. The Lancet profile →
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

2020 233 citations Atul Deodhar, Philip Helliwell et al. The Lancet profile →

Peers

Countries citing papers authored by Elizabeth C. Hsia

Since Specialization

Citations

This map shows the geographic impact of Elizabeth C. Hsia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth C. Hsia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth C. Hsia more than expected).

Fields of papers citing papers by Elizabeth C. Hsia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth C. Hsia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth C. Hsia. The network helps show where Elizabeth C. Hsia may publish in the future.

Co-authorship network of co-authors of Elizabeth C. Hsia

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth C. Hsia. A scholar is included among the top collaborators of Elizabeth C. Hsia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth C. Hsia. Elizabeth C. Hsia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials 2023 ·ACR Open Rheumatology ·Stefan Siebert,Kristen Sweet,Christopher T. Ritchlin,Elizabeth C. Hsia,Alexa P. Kollmeier,Xie L. Xu,Loqmane Seridi,Qingxuan Song,Sheng Gao,(unknown),Michelle Miron	2
2	Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis 2022 ·Arthritis Research & Therapy ·M. Elaine Husni,Atul Deodhar,Sergio Schwartzman,Soumya D. Chakravarty,Elizabeth C. Hsia,Jocelyn H. Leu,Yiying Zhou,Kim Hung Lo,Arthur Kavanaugh	11
3	Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis 2022 ·JCR Journal of Clinical Rheumatology ·Atul Deodhar,Soumya D. Chakravarty,Natalie J. Shiff,Kim Hung Lo,Stephen Xu,Elizabeth C. Hsia,Abhijeet Danve,John D. Reveille	1
4	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial 2021 ·Clinical Rheumatology ·Alexis Ogdie,Jessica A. Walsh,Soumya D. Chakravarty,Steven L. Peterson,Kim Hung Lo,Lilianne Kim,Nan Li,Elizabeth C. Hsia,Eric K. H. Chan,Arthur Kavanaugh,M. Elaine Husni	3
5	Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis 2021 ·Arthritis & Rheumatology ·Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,Xie L. Xu,(unknown),Shihong Sheng,M. Shawi,Soumya D. Chakravarty,Désirée van der Heijde,Philip J. Mease	66
6	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced 2021 ·RMD Open ·Christopher T. Ritchlin,Philip Helliwell,Wolf‐Henning Boehncke,Enrique R. Soriano,Elizabeth C. Hsia,Alexa P. Kollmeier,Soumya D. Chakravarty,(unknown),Ramanand A. Subramanian,Xie L. Xu,Qing Zuraw,Shihong Sheng,(unknown),Prasheen Agarwal,Bei Zhou,Yanli Zhuang,M. Shawi,Chetan S. Karyekar,Atul Deodhar	50
7	Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis 2020 ·Arthritis & Rheumatology ·Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,Soumya D. Chakravarty,Xie L. Xu,Ramanand A. Subramanian,Prasheen Agarwal,Shihong Sheng,(unknown),Bei Zhou,Yanli Zhuang,Désirée van der Heijde,Philip J. Mease	56
8	Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study 2020 ·ACR Open Rheumatology ·Philip J. Mease,M. Elaine Husni,Soumya D. Chakravarty,Shelly Kafka,Dennis Parenti,Lilianne Kim,Kim Hung Lo,Elizabeth C. Hsia,Arthur Kavanaugh	9
9	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial 2020 ·Value in Health ·John D. Reveille,Atul Deodhar,Akgun Ince,Eric K. H. Chan,Steven L. Peterson,Nan Li,Elizabeth C. Hsia,Lilianne Kim,Kim Hung Lo,Stephen Xu,Diane D. Harrison,Chenglong Han	6
10	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial 2020 ·Value in Health ·M. Elaine Husni,Arthur Kavanaugh,Eric K. H. Chan,Steven L. Peterson,Nan Li,Elizabeth C. Hsia,Lilianne Kim,Kim Hung Lo,Diane D. Harrison,Chenglong Han	4
11	Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial 2020 ·Arthritis Research & Therapy ·Philip J. Mease,M. Elaine Husni,Shelly Kafka,Soumya D. Chakravarty,Diane D. Harrison,Kim Hung Lo,Stephen Xu,Elizabeth C. Hsia,Arthur Kavanaugh	6
12	Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis 2019 ·Arthritis Care & Research ·M. Elaine Husni,Arthur Kavanaugh,Frederick T. Murphy,(unknown),Diane D. Harrison,Lilianne Kim,Kim Hung Lo,Jocelyn H. Leu,Elizabeth C. Hsia	16
13	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial 2015 ·The Journal of Rheumatology ·Edward Keystone,Mark C. Genovese,Stephen Hall,Sang‐Cheol Bae,Chenglong Han,Timothy Gathany,Stephen Xu,Yiying Zhou,Jocelyn H. Leu,Elizabeth C. Hsia	35
14	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis 2013 ·Lara D. Veeken ·Daniel E. Fürst,Jonathan Kay,Mary Chester Wasko,Edward Keystone,Arthur Kavanaugh,Atul Deodhar,Frederick T. Murphy,Jeanette H. Magnus,Elizabeth C. Hsia,Benjamin Hsu,Stephen Xu,Mahboob U. Rahman,Mittie K. Doyle	26
15	Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial 2013 ·Annals of the Rheumatic Diseases ·Joshua F. Baker,Mikkel Østergaard,Paul Emery,Elizabeth C. Hsia,Jiandong Lu,Daniel G. Baker,Philip G. Conaghan	57
16	Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials 2013 ·Value in Health ·Ingrid Strusberg,Bernardo A. Pons‐Estel,Pedro C. Miranda,Mark C. Genovese,Roy Fleischmann,Andrea Puig,Chenglong Han,Elizabeth C. Hsia	1
17	Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension 2013 ·The Journal of Rheumatology ·Edward Keystone,Mark C. Genovese,Stephen Hall,Pedro C. Miranda,Sang‐Cheol Bae,William Palmer,(unknown),Stephen Xu,Elizabeth C. Hsia	33
18	Paediatric and Adolescent Rheumatology [213-214] 2009 ·Lara D. Veeken ·Paul Emery,Roy Fleischmann,Larry W. Moreland,Elizabeth C. Hsia,W. Xu,(unknown)	1
19	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialbreakdown → 2009 ·The Lancet ·Josef S Smolen,Jonathan Kay,Mittie K. Doyle,Robert Landewé,Eric L. Matteson,J. Wollenhaupt,Norman Gaylis,Frederick T. Murphy,Jeffrey Neal,Yiying Zhou,Sudha Visvanathan,Elizabeth C. Hsia,Mahboob U. Rahman	423
20	Management of Aortic Disease in Marfan Syndrome 2005 ·Archives of Internal Medicine ·Seoyoung C. Kim,Neil A. Martin,Elizabeth C. Hsia,Reed E. Pyeritz,Daniel Albert	33

About Elizabeth C. Hsia

Elizabeth C. Hsia is a scholar working on Rheumatology, Hematology and Genetics, having authored 109 papers that have together received 3.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (67 papers), Autoimmune and Inflammatory Disorders Research (53 papers) and Spondyloarthritis Studies and Treatments (40 papers). The work is most often cited by research in Rheumatology (3.1k citations), Hematology (1.6k citations) and Immunology (1.7k citations). Elizabeth C. Hsia has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Mahboob U. Rahman, Jonathan Kay, Eric L. Matteson, Mittie K. Doyle, Sudha Visvanathan, Yiying Zhou, Roy Fleischmann, Atul Deodhar, Alexa P. Kollmeier and Paul Emery. Their work appears in journals such as The Lancet, Annals of the Rheumatic Diseases and Journal of Investigative Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact